Innate Pharma S.A. is a French biotechnology company that develops immunotherapies for cancer and inflammatory diseases. The company's products are based on natural killer (NK) cells, which are part of the innate immune system. Innate Pharma's lead product candidate is monalizumab, which is being developed for the treatment of various types of cancer. The company was founded in 1999 and is headquartered in Marseille, France.